Here, we evaluated seven sequence-varied rVAR2 for their detectability of the unique cancer-derived ofCS glycan or ofCSPGs, and established and validated the plasma ofCS-CD44 as a novel pan-cancer biomarker. Here, CD44 is linked to cancer.